AngioDynamics Historical Income Statement

ANGO Stock

USD 6.17 0.05 0.82%

Historical analysis of AngioDynamics income statement accounts such as Interest Expense of 1.6 M, Total Revenue of 242.9 M or Gross Profit of 129.6 M can show how well AngioDynamics performed in making a profits. Evaluating AngioDynamics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AngioDynamics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AngioDynamics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AngioDynamics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

About AngioDynamics Income Statement Analysis

AngioDynamics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AngioDynamics shareholders. The income statement also shows AngioDynamics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AngioDynamics Income Statement Chart

AngioDynamics Income Statement is one of the three primary financial statements used for reporting AngioDynamics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of AngioDynamics revenue and expense. AngioDynamics Income Statement primarily focuses on the company's revenues and expenses during a particular period.

As of the 26th of May 2024, Discontinued Operations is likely to grow to about 87.5 M, while Depreciation And Amortization is likely to drop about 17.8 M.

Depreciation And Amortization Total Revenue Gross Profit Other Operating Expenses Research Development Interest Income

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Total Revenue

Total revenue comprises all receipts AngioDynamics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of AngioDynamics minus its cost of goods sold. It is profit before AngioDynamics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AngioDynamics. It is also known as AngioDynamics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Most accounts from AngioDynamics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AngioDynamics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.As of the 26th of May 2024, Discontinued Operations is likely to grow to about 87.5 M, while Depreciation And Amortization is likely to drop about 17.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	165.7M	174.2M	200.4M	129.6M
Total Revenue	316.2M	338.8M	389.6M	242.9M

Gross Profit Total Revenue

AngioDynamics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Net Interest Income	Interest Income	Discontinued Operations	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.56	0.86	0.83	0.91	-0.15	-0.06	0.8	0.13	0.87	0.89	-0.09	-0.09	-0.12	0.11	0.82	0.87	-0.13	-0.13	0.02	0.18	0.14	-0.24	0.29	0.47	0.42
Interest Expense	0.56		0.71	0.65	0.6	0.6	0.64	0.34	0.77	0.75	0.41	0.47	0.19	0.43	0.19	0.23	0.39	0.31	-0.71	-0.29	0.14	-0.61	0.51	-0.18	-0.02	-0.13
Total Revenue	0.86	0.71		0.99	0.98	0.17	0.26	0.83	0.44	0.99	0.9	0.12	-0.01	0.09	0.14	0.7	0.86	0.06	-0.29	-0.1	0.18	-0.07	0.0	0.13	0.23	0.22
Gross Profit	0.83	0.65	0.99		0.98	0.12	0.23	0.88	0.41	0.96	0.93	0.06	-0.09	0.04	0.09	0.75	0.88	-0.02	-0.22	-0.03	0.13	-0.02	-0.05	0.21	0.24	0.3
Other Operating Expenses	0.91	0.6	0.98	0.98		-0.02	0.08	0.9	0.28	0.96	0.96	-0.02	-0.09	-0.04	0.11	0.81	0.94	-0.07	-0.14	-0.01	0.16	0.07	-0.17	0.27	0.36	0.37
Operating Income	-0.15	0.6	0.17	0.12	-0.02		0.92	-0.22	0.87	0.2	-0.23	0.72	0.35	0.69	0.14	-0.38	-0.3	0.57	-0.75	-0.39	0.04	-0.66	0.9	-0.63	-0.61	-0.56
Ebit	-0.06	0.64	0.26	0.23	0.08	0.92		-0.11	0.97	0.29	-0.11	0.73	0.32	0.68	0.19	-0.34	-0.2	0.54	-0.8	-0.4	0.1	-0.7	0.94	-0.61	-0.58	-0.53
Research Development	0.8	0.34	0.83	0.88	0.9	-0.22	-0.11		0.06	0.77	0.96	-0.23	-0.26	-0.21	-0.07	0.87	0.89	-0.26	0.1	0.17	0.0	0.35	-0.37	0.49	0.34	0.6
Ebitda	0.13	0.77	0.44	0.41	0.28	0.87	0.97	0.06		0.47	0.07	0.71	0.31	0.66	0.21	-0.17	-0.01	0.51	-0.83	-0.41	0.14	-0.7	0.87	-0.5	-0.46	-0.45
Cost Of Revenue	0.87	0.75	0.99	0.96	0.96	0.2	0.29	0.77	0.47		0.85	0.18	0.07	0.14	0.19	0.65	0.83	0.13	-0.36	-0.18	0.22	-0.12	0.04	0.04	0.22	0.13
Total Operating Expenses	0.89	0.41	0.9	0.93	0.96	-0.23	-0.11	0.96	0.07	0.85		-0.21	-0.23	-0.22	0.02	0.91	0.98	-0.25	0.08	0.14	0.1	0.24	-0.36	0.46	0.47	0.57
Income Before Tax	-0.09	0.47	0.12	0.06	-0.02	0.72	0.73	-0.23	0.71	0.18	-0.21		0.87	0.97	0.11	-0.38	-0.21	0.91	-0.55	-0.9	0.04	-0.69	0.76	-0.48	-0.2	-0.46
Total Other Income Expense Net	-0.09	0.19	-0.01	-0.09	-0.09	0.35	0.32	-0.26	0.31	0.07	-0.23	0.87		0.86	0.07	-0.35	-0.16	0.91	-0.25	-0.99	0.02	-0.45	0.41	-0.35	0.08	-0.37
Net Income	-0.12	0.43	0.09	0.04	-0.04	0.69	0.68	-0.21	0.66	0.14	-0.22	0.97	0.86		-0.11	-0.35	-0.22	0.93	-0.5	-0.87	-0.18	-0.65	0.71	-0.41	-0.17	-0.38
Income Tax Expense	0.11	0.19	0.14	0.09	0.11	0.14	0.19	-0.07	0.21	0.19	0.02	0.11	0.07	-0.11		-0.11	0.05	-0.09	-0.19	-0.11	0.98	-0.17	0.22	-0.32	-0.14	-0.33
Selling General Administrative	0.82	0.23	0.7	0.75	0.81	-0.38	-0.34	0.87	-0.17	0.65	0.91	-0.38	-0.35	-0.35	-0.11		0.89	-0.43	0.35	0.31	0.02	0.37	-0.54	0.69	0.59	0.8
Selling And Marketing Expenses	0.87	0.39	0.86	0.88	0.94	-0.3	-0.2	0.89	-0.01	0.83	0.98	-0.21	-0.16	-0.22	0.05	0.89		-0.22	0.14	0.09	0.12	0.18	-0.42	0.49	0.62	0.55
Net Income From Continuing Ops	-0.13	0.31	0.06	-0.02	-0.07	0.57	0.54	-0.26	0.51	0.13	-0.25	0.91	0.91	0.93	-0.09	-0.43	-0.22		-0.47	-0.93	-0.17	-0.51	0.58	-0.56	-0.17	-0.55
Non Operating Income Net Other	-0.13	-0.71	-0.29	-0.22	-0.14	-0.75	-0.8	0.1	-0.83	-0.36	0.08	-0.55	-0.25	-0.5	-0.19	0.35	0.14	-0.47		0.34	-0.06	0.58	-0.78	0.67	0.49	0.63
Non Recurring	0.02	-0.29	-0.1	-0.03	-0.01	-0.39	-0.4	0.17	-0.41	-0.18	0.14	-0.9	-0.99	-0.87	-0.11	0.31	0.09	-0.93	0.34		-0.05	0.47	-0.46	0.38	-0.03	0.39
Tax Provision	0.18	0.14	0.18	0.13	0.16	0.04	0.1	0.0	0.14	0.22	0.1	0.04	0.02	-0.18	0.98	0.02	0.12	-0.17	-0.06	-0.05		-0.09	0.11	-0.2	-0.07	-0.22
Net Interest Income	0.14	-0.61	-0.07	-0.02	0.07	-0.66	-0.7	0.35	-0.7	-0.12	0.24	-0.69	-0.45	-0.65	-0.17	0.37	0.18	-0.51	0.58	0.47	-0.09		-0.76	0.35	0.08	0.42
Interest Income	-0.24	0.51	0.0	-0.05	-0.17	0.9	0.94	-0.37	0.87	0.04	-0.36	0.76	0.41	0.71	0.22	-0.54	-0.42	0.58	-0.78	-0.46	0.11	-0.76		-0.68	-0.59	-0.61
Discontinued Operations	0.29	-0.18	0.13	0.21	0.27	-0.63	-0.61	0.49	-0.5	0.04	0.46	-0.48	-0.35	-0.41	-0.32	0.69	0.49	-0.56	0.67	0.38	-0.2	0.35	-0.68		0.66	0.93
Reconciled Depreciation	0.47	-0.02	0.23	0.24	0.36	-0.61	-0.58	0.34	-0.46	0.22	0.47	-0.2	0.08	-0.17	-0.14	0.59	0.62	-0.17	0.49	-0.03	-0.07	0.08	-0.59	0.66		0.62
Extraordinary Items	0.42	-0.13	0.22	0.3	0.37	-0.56	-0.53	0.6	-0.45	0.13	0.57	-0.46	-0.37	-0.38	-0.33	0.8	0.55	-0.55	0.63	0.39	-0.22	0.42	-0.61	0.93	0.62

Click cells to compare fundamentals

AngioDynamics Account Relationship Matchups

AngioDynamics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	23.8M	25.9M	29.3M	30.9M	35.5M	17.8M
Interest Expense	907K	861K	688K	2.7M	3.1M	1.6M
Total Revenue	264.2M	291.0M	316.2M	338.8M	389.6M	242.9M
Gross Profit	150.3M	156.8M	165.7M	174.2M	200.4M	129.6M
Other Operating Expenses	278.2M	306.0M	334.4M	357.4M	411.0M	233.3M
Operating Income	(14.2M)	(14.9M)	(19.0M)	(19.2M)	(17.3M)	(16.4M)
Ebit	(14.2M)	(14.9M)	(19.0M)	(19.2M)	(22.1M)	(21.0M)
Research Development	29.7M	36.4M	30.7M	29.9M	34.4M	21.4M
Ebitda	9.6M	11.0M	10.3M	11.6M	13.4M	12.7M
Cost Of Revenue	113.9M	134.2M	150.5M	164.5M	189.2M	113.3M
Total Operating Expenses	164.3M	171.8M	183.9M	192.9M	221.9M	120.0M
Income Before Tax	(167.1M)	(36.1M)	(29.9M)	(54.4M)	(49.0M)	(46.5M)
Total Other Income Expense Net	(153.0M)	(21.2M)	(10.9M)	(35.2M)	(31.7M)	(30.1M)
Net Income	(165.8M)	(31.5M)	(26.5M)	(52.4M)	(47.2M)	(44.8M)
Income Tax Expense	(1.3M)	(4.5M)	(3.4M)	(2.0M)	(1.8M)	(1.7M)
Selling General Administrative	37.9M	35.9M	38.5M	40.0M	46.0M	27.5M
Net Income Applicable To Common Shares	(166.8M)	(31.5M)	(26.5M)	(52.4M)	(47.2M)	(44.8M)
Selling And Marketing Expenses	78.6M	81.3M	95.3M	104.2M	119.9M	73.9M
Net Income From Continuing Ops	(166.8M)	(31.5M)	(26.5M)	(52.4M)	(47.2M)	(44.8M)
Non Operating Income Net Other	(1.0M)	92K	(790K)	(554K)	(637.1K)	(669.0K)
Non Recurring	153.1M	20.3M	10.3M	32.5M	37.4M	30.9M
Tax Provision	(1.3M)	(4.5M)	(3.4M)	(2.0M)	(1.8M)	(1.7M)
Net Interest Income	(907K)	(861K)	(688K)	(2.7M)	(3.1M)	(3.3M)
Reconciled Depreciation	23.8M	25.9M	29.3M	30.9M	35.5M	28.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:

How To Invest In AngioDynamics

Details

Is AngioDynamics Stock a good investment?

Details

What is AngioDynamics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk

Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.80)

Revenue Per Share

8.105

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.05)

Return On Equity

(0.62)

The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AngioDynamics Historical Income Statement

About AngioDynamics Income Statement Analysis

AngioDynamics Income Statement Chart

Depreciation And Amortization

Total Revenue

Gross Profit

Other Operating Expenses

Interest Income

AngioDynamics income statement Correlations

AngioDynamics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AngioDynamics income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for AngioDynamics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Total Revenue
Other Operating Expenses	+ 0.98	Total Revenue
Other Operating Expenses	+ 0.98	Gross Profit
Selling And Marketing Expenses	+ 0.98	Total Operating Expenses
Tax Provision	+ 0.98	Income Tax Expense

Non Recurring	- 0.99	Total Other Income Expense Net
Non Recurring	- 0.93	Net Income From Continuing Ops
Non Recurring	- 0.9	Income Before Tax
Non Recurring	- 0.87	Net Income
Non Operating Income Net Other	- 0.83	Ebitda
Non Operating Income Net Other	- 0.8	Ebit